NLS Pharmaceutics AG has announced an amendment to their Securities Purchase Agreement, originally dated March 27, 2025. The amendment involves a subsequent closing where the company is required to issue 606,061 Preferred Shares. However, at present, only 37,783 Preferred Shares and 591,532 preferred participation certificates are authorized for issuance. This update is part of the company's ongoing efforts to manage its securities transactions and has been disclosed in a recent filing with the Securities and Exchange Commission.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-059248), on June 30, 2025, and is solely responsible for the information contained therein.